HC Wainwright Begins Coverage on Emergent BioSolutions (NYSE:EBS)

Analysts at HC Wainwright started coverage on shares of Emergent BioSolutions (NYSE:EBS) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 81.38% from the company’s current price.

A number of other analysts have also recently issued reports on the stock. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday. Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Down 1.8 %

EBS opened at $8.27 on Monday. The company has a market capitalization of $448.10 million, a PE ratio of -2.02 and a beta of 1.59. The business has a 50-day moving average of $9.21 and a 200-day moving average of $8.89. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Institutional Investors Weigh In On Emergent BioSolutions

Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new stake in shares of Emergent BioSolutions in the second quarter worth $41,000. Verus Capital Partners LLC bought a new position in Emergent BioSolutions in the 2nd quarter worth $68,000. Vanguard Personalized Indexing Management LLC bought a new stake in Emergent BioSolutions during the second quarter valued at about $93,000. Stifel Financial Corp acquired a new stake in shares of Emergent BioSolutions in the third quarter valued at about $96,000. Finally, Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions in the second quarter worth about $97,000. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.